Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0546837 (esophageal cancer)
 8,907 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Combination chemotherapy with cis-diamminedichloroplatinum (CDDP) and other anticancer agents was performed in patients with advanced esophageal cancer. From July 1982 to September 1984, 16 patients were entered into this study and divided into two regimens. In regimen I, 5 patients were treated with a daily dose of 20 mg CDDP and 10 mg Peplomycin for five consecutive days and 10 mg Mitomycin C on the first day. This course was repeated 2 or 3 times every 4 weeks. As for evaluation, 1 PR (20%) and 4 NC (80%) were observed. In regimen II, nine patients were treated with daily doses of 25 mg CDDP and 2 mg Vindesine for 5 consecutive days, a course which was repeated every 4 weeks. As for evaluation, 1 CR (9%), 1 PR (9%), 4 MR (36%), 2NC (18%), and 3 PD (27%) were observed. Major side effects were renal failure, bone marrow suppression, nausea and vomiting, which were mostly transient. However, more severe bone marrow suppression was observed in regimen I composed with regimen II.
 ...
PMID:[Combination chemotherapy with cis-diamminedichloroplatinum (CDDP) and other anticancer agents for patients with advanced esophageal cancer]. 240 79

The prognosis of patients with squamous cell carcinoma of the esophagus remains dismal, in spite of technical advances in both surgery and radiation therapy. Chemotherapy as a palliative approach is still in the investigational phase and the very moderate antitumor activity has been observed with only a few single agents (Bleomycin, Adriamycin, Cis Platinum, 5-Fluorouracil, Vindesine). In an attempt to improve therapeutic results, cytostatic agents, which interacts with radiation, are now combined with radiotherapy. In a sequential manner several controlled clinical studies were performed in more than 250 patients, using antitumor drugs alone or in combination with radiation. The results of these studies showed superiority of combined approach, either in remission rate or remission duration. Combination of Bleomycin + radiation achieved a response rate of 62%, Adriamycin + radiation 60%, while both drugs combined with radiation showed the same response rate but higher toxicity. By adding 5-Fluorouracil to Adriamycin/Bleomycin + radiation therapy, 64% and even 75% responses were observed compared to only 30-40% with cytostatics alone. With combined approach a median remission duration of 16 months was reached. An ongoing clinical trial, based upon in vitro proved synergism of 4-epi-doxorubicin and radiation, showed very promising results. Namely, this new analogue of Adriamycin, when combined with radiation, resulted in 6 complete and 7 partial remissions out of 17 patients entered the study (13/17 - 76%). Furthermore, 4 patients showed a minor regression (less than 50%), and no progression was observed. The advantages of chemoradiotherapy in esophageal cancer could be summarized as follows: higher response rate (60-80%), higher proportion of complete responses (up to 45%), longer remission duration, lower radiation dosage (3,200-4,000 cGy) and consequently better tolerance of treatment (less morbidity). The longer follow up will show, whether combined approach could increase 5-year survival rate of these patients.
 ...
PMID:Combination of cytostatics and radiation--a new trend in the treatment of inoperable esophageal cancer. 241 19

Subrenal Capsule Assay (SRCA) as a chemosensitivity test was performed on 14 esophageal squamous cell carcinomas in order to select a more effective form of chemotherapy. Of the 14 assays, 12 were evaluable. Mice were treated with anticancer agents (e.g. Cisplatin, Bleomycin, Methotrexate, Vindesine) on days 1 and 3 after transplantation, and on day 6, the sensitivities were determined. Fresh esophageal cancers yielded an evaluable assay rate of 74%. The implant grew progressively for six days in the remaining group of control mice. Histologically, host cell infiltration at the border of the implant was observed from day 3 after transplantation, and cells had degenerated or had been partially replaced by scar tissue by day 6. The results of chemosensitivity tests differed according to the anticancer agent used or from case to case. Clinically, correspondence between the assay results and clinical results was obtained in 5 out of 7 cases. SRCA is a new promising chemosensitivity test which is clinically useful, and the present results indicated the feasibility of its use in developing an effective chemotherapy for esophageal cancer.
 ...
PMID:[A 6-day subrenal capsule assay for predictive testing of primary esophageal cancers]. 243 79

A cooperative phase II study of vindesine, a new vinca alkaloid, was carried out in 16 major institutions. The selection of patients and evaluation of tumor response were based on the Criteria for the Evaluation of Tumor Response by Chemotherapy in Solid Tumor Patients by Koyama and Saito. Vindesine was administered by i.v. bolus injection at a dose of 3 mg per week. Out of 130 patients who entered into the study, 117 patients were evaluable. Partial responses were obtained in 16 (13.7%) out of 117 evaluable patients, including 7 (17.1%) out of 41 lung cancer, 3 (8.1%) out of 37 breast cancer, 2 (33.3%) out of 6 esophageal cancer, and one each of cervical cancer, liposarcoma, rhabdomyosarcoma, and embryonic tumor. Major side effects were leukopenia (less than 3000/cm) 60.2%, gastrointestinal disturbances 23.6%, neurotoxicity 25.2% and hair loss 14.2%.
 ...
PMID:[A cooperative phase II study of vindesine sulfate in patients with solid tumors]. 661 38